Rigel Pharmaceuticals | RIGL - Pre Tax Profit


Rigel Pharmaceuticals reported $-1.03M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Agenus USD -10.61M 263.52M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
AstraZeneca USD 3.24B 117M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Celldex Therapeutics USD -81.32M 14.27M Dec/2025
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Eli Lilly USD 7.23B 456M Sep/2025
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Intrexon USD -60.48M 27.09M Jun/2024
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Karyopharm Therapeutics USD -30.89M 1.16M Dec/2024
Ligand Pharmaceuticals USD 141.14M 102M Sep/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Pfizer USD 3.33B 290M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
Veracyte USD 40.63M 21.74M Dec/2025